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http://dxObjectives: The study objective was to review a single-center experience on robotic mitral valve repair to treat
mitral regurgitation, with a specific focus on midterm echocardiographic mitral durability. No data assessing the
quality or durability of repaired mitral valves are currently available.
Methods: A total of 200 patients who underwent robotic mitral regurgitation repair using the da Vinci system
(Intuitive Surgical, Inc, Sunnyvale, Calif) between August 2007 and December 2012 were evaluated. Serial
echocardiographic results and operative and procedural times were analyzed.
Results:Mitral regurgitation repairs were successfully performed, and no or mild residual mitral regurgitation
developed in 98.0% of patients, with no conversion to sternotomy. No in-hospital deaths occurred. Follow-up
was completed in 96.5% of patients with a median of 31.4 months (interquartile range, 12.4-42.3 months).
During follow-up, 4 late deaths, 2 strokes, 1 low cardiac output, 1 newly required dialysis, and 1 reoperation
for mitral regurgitation occurred. Freedom from major adverse cardiac events at 5 years was 87.7%  5.1%.
Regular echocardiographic follow-up (>6 months) was achieved in 187 patients (93.5%). At a median of
29.6 months (interquartile range, 14.9-45.8 months), 21 patients (10.5%) demonstrated moderate or greater
mitral regurgitation. Freedom from moderate or greater mitral regurgitation at 5 years was 87.0%  2.6%.
Mean cardiopulmonary bypass and crossclamping times were 182.9  48.4 minutes and 110.9  34.1 minutes,
respectively, demonstrating a significant decrease in both times according to the chronologic date of surgery.
Conclusions: Robotic mitral regurgitation repair is technically feasible and efficacious, demonstrating
favorable midterm mitral durability and improved procedural times as experience increases. (J Thorac Cardio-
vasc Surg 2014;148:2773-9)A
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DRobotic mitral valve (MV) repair is a proven and acceptable
approach for treating complex MV diseases, especially in
centers experienced with minimally invasive cardiac sur-
gery (MICS) techniques and the da Vinci surgical system
(Intuitive Surgical, Inc, Sunnyvale, Calif).1,2 Studies
report excellent early outcomes after robotic MV repair,
and the full anatomic correction of the mitral leaflet and
annulus using minithoracotomy incision and robotic
assistance is a safe and effective approach for all types of
degenerative MV pathology.3-6
As for the validity of MV repair usingMICS, it still needs
to be clearly demonstrated that the procedure provides
complete surgical correction. To do so, the long-term
durability of repaired MV function should be addressed
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The Journal of Thoracic and Carefficacy of MV repair using the robotic approach. Although
there are several reports on postoperative mortality/
morbidity and long-term freedom from mitral reoperation
(ie, repair or replacement), data on the long-term echocar-
diographic outcomes of MV repair are scarce. Of the
published studies on the surgical outcomes of robotic
MV repair, only a few include intermediate to long-term
echocardiographic follow-up examinations3,4,7,8; however,
even those studies only report the last echocardiographic
results, and only 1 study reported 5-year Kaplan–Meier
freedom from reoperation.4 In this regard, no study
reports the long-term quality of the repaired MVs (eg,
regurgitation or stenosis) or freedom from significant
mitral regurgitation (MR) recurrence according to results
obtained using long-term regular echocardiographic
follow-up. Thus, we assessed in the current study our
experience of robotic MV repairs, with a specific focus on
the midterm echocardiographic outcomes of repaired MVs.METHODS
Patients
Between August 2007 and December 2012, 369 MICS procedures were
performed at the Asan Medical Center using the da Vinci surgical system.
Of these, 209 patients underwent MV repair. After excluding patients
whose MV pathology was diagnosed as mitral stenosis, a total of 200
consecutive patients who had MV repair for MR with or withoutdiovascular Surgery c Volume 148, Number 6 2773
Abbreviations and Acronyms
ACC ¼ aortic crossclamping
AF ¼ atrial fibrillation
CPB ¼ cardiopulmonary bypass
IQR ¼ interquartile range
MICS ¼ minimally invasive cardiac surgery
MR ¼ mitral regurgitation
MV ¼ mitral valve
TAP ¼ tricuspid annuloplasty
TEE ¼ transesophageal echocardiography
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ablation were identified. The exclusion criteria for robotic MV repair
included patients who required an additional cardiac procedure (eg, aortic
valve surgery, coronary artery bypass grafting) and patients with risk
factors that could affect the MICS approach (eg, peripheral arterial
obstructive disease, severely tortuous abdominal aorta, severe cardiome-
galy, and difficult chest wall shape for port-access surgery). Robotic MV
repairs were performed by a single console surgeon (J.W.L.), along with
5 bedside surgeons. The choice of robot-assisted cardiac surgery primarily
depended on the condition of the patient and preferences decided after
providing informed consent. We retrospectively reviewed preoperative
characteristics, early and late clinical outcomes, and echocardiographic
results.
This study was approved by the Asan Medical Center Ethics
Committee/Review Board, which waived the requirement for informed
patient consent because of the retrospective nature of the analysis.
Operative Technique
Conventional general anesthesia with dual-lumen endotracheal
intubation and single left-lung ventilation was used in all patients.
A transesophageal echocardiography (TEE) probe was inserted after
intubation, and external defibrillator patches were attached to the back.
After percutaneous superior vena caval cannulation through the right
internal jugular vein, patients were placed in the supine position with the
right chest elevated approximately 30. Cardiopulmonary bypass (CPB)
was established by cannulating the femoral artery and vein. If atheroscle-
rotic burden was identified anywhere in the aortic arch or descending
thoracic or abdominal aorta on preoperative computed tomography
imaging, an alternative aortic cannulation technique was used (eg, axillary
or direct transthoracic ascending aortic cannulation). A 4-cmminithoracot-
omy horizontal incision was made in the fourth intercostal space in the
mid-axillary line, and a dynamic left atrial retractor was placed in the
mid-clavicular line. The left arm of the robot was inserted through the third
intercostal space in the anterior-axillary line, and the right armwas inserted
through the sixth intercostal space in the mid-axillary line. A Chitwood
transthoracic aortic clamp (Scanlan International Inc, St Paul, Minn) was
placed posterior to the mid-axillary line in the third intercostal
space. The chest cavity was flooded with carbon dioxide to mitigate
intracavitary air. Femoral cannulation was performed through a 2-cm
oblique infrainguinal incision with anterior exposure of the femoral
vessels. Vacuum-assisted venous drainage was used during CPB, and
myocardial protection was achieved using antegrade cold crystalloid
cardioplegic solution (Custodiol HTK; K€ohler Chemie GmbH, Bensheim,
Germany). After cardioplegic arrest and aortic crossclamping (ACC), the
MV was exposed through the interatrial groove. Standard mitral repair
techniques were used.
Among patients who required right atriotomy for concomitant TAP or
AF ablation procedures, the superior vena cavaewere snared using Bulldog
clamps. Concomitant TAPs were conducted in 26 patients (13.0%), and2774 The Journal of Thoracic and Cardiovascular Surconcomitant maze procedures were performed in 44 patients (22.0%)
in whom the modified Cox-maze III procedure with argon-based
cryothermy (Cardioblate CryoFlex Surgical Ablation Probe; Medtronic,
Inc, Minneapolis, Minn) was performed. Details regarding our modified
AF ablation lesion set were previously described.9
Echocardiographic Evaluation
All patients underwent 2-dimensional echocardiographic analysis and
Doppler color-flow imaging using HP Sonos 5500 (Hewlett-Packard,
Andover, Mass), Philips iE33 (Philips Medical Systems, Bothell, Wash),
and GE vivid 7, E9 (GEMedical System, Horten, Norway) in the 2 months
leading up to surgery. Preoperative TEE was also performed to more
accurately analyze MV morphology. Immediate postoperative TEE was
confirmed by a cardiologist in the operating room after the patient was
weaned fromCPB, and all patients underwent transthoracic echocardiogra-
phy before discharge. MR was detected and semiquantitatively graded as
mild, moderate, or severe, using color Doppler flow imaging.10
Follow-up
Data were obtained until November 2013, through biannual visits to the
outpatient clinic. Early mortality was defined as death within 30 days of
surgery. Data on vital status, date of death, and causes of death were
obtained from the Korean national registry of vital statistics. Major adverse
cardiac and cerebrovascular events were defined as all-cause death or
valve-related complications, the latter of which included thromboembo-
lism, reoperation, infective endocarditis, and warfarin-related hemorrhage.
Serial echocardiographic follow-up examinations were performed to
detect MR recurrence. Recurrent MR was defined as moderate or greater
MR (ie, proximal isovelocity surface area radius>0.4 cm).
Statistical Analysis
Categoric variables are presented as frequencies and percentages.
Continuous variables are expressed as the means  standard deviations
or medians with ranges. The cumulative incidence rates of major
event-free survival and freedom from MR were estimated using the
Kaplan–Meier method. To assess learning period effects, CPB, ACC,
and operative times (skin-to-skin) were reviewed on the basis of the
chronologic date of surgery and analyzed using bivariate correlation
analysis. All reported P values are 2-sided. All statistical analyses were
performed using SPSS, version 18.0 (IBM, Armonk, NY).RESULTS
Baseline Characteristics and Operative Data
The preoperative patient characteristics are listed in
Table 1. Median age was 47 years (interquartile range
[IQR], 36-57 years), and 26.5% of patients were classified
with New York Heart Association functional class III/IV.
Preoperative MR grade was moderate-to-severe in 17
patients (8.5%) and severe in 183 patients (91.5%). Two
patients underwent prior cardiac surgeries via sternotomy;
1 patient received ventricular septal defect closure, and 1
patient underwent MV repair. In both cases, we used
transthoracic clamps with routine antegrade cardioplegic
infusion via root cannulation.
Robotic MR repairs were successfully performed in
100% of patients with no, trivial, or mild residual MR
(proximal isovelocity surface area radius 0.4 cm) noted
on intraoperative TEE (confirmed by the cardiologist) after
weaning off CPB without intraoperative conversion togery c December 2014
TABLE 1. Baseline patient profiles (n ¼ 200)
Characteristics n (%) or mean ± SD
Demography
Male 120 (60.0)
Age (y), median (IQR) 47 (36-57)
Body surface area 1.7  0.2
Clinical data
NYHA Fc III or IV 53 (26.5)
AF 45 (22.5)
Hypertension 61 (30.5)
Diabetes mellitus 12 (6.0)
History of stroke 8 (4.0)
Chronic obstructive pulmonary disease 4 (2.0)
Chronic kidney disease 3 (1.5)
Previous sternotomy 2 (1.0)
Echocardiographic data
LV ejection fraction (%) 62.66  6.2
LV systolic dimension (mm) 37.7  5.3
LV diastolic dimension (mm) 59.6  6.4
LA dimension (mm) 47.5  9.0
Tricuspid regurgitation grade (>2þ) 10 (5.0)
RV-RA DP (mm Hg) 29.6  11.9
MR grade
Severe 183 (91.5)
Moderate-to-severe 17 (8.5)
MV leaflet prolapse subsets
Anterior leaflet 48 (24.0)
Bileaflet 47 (23.5)
Posterior leaflet 105 (52.5)
Cause of MR
Degenerative 160 (80.0)
Rheumatic 18 (9.0)
Infective endocarditis 18 (9.0)
Congenital 4 (2.0)
AF, Atrial fibrillation; IQR, interquartile range; LA, left atrium; LV, left ventricle;
MR, mitral regurgitation; MV, mitral valve; NYHA Fc, New York Heart Association
functional class; RV-RA DP, right ventricular-right atrial pressure gradient;
SD, standard deviation.
FIGURE 1. Results at the preoperative, immediately postoperative, and
last follow-up echocardiographic examinations. *One patient required
reoperation for recurring mitral regurgitation.
TABLE 2. Operative characteristics (n ¼ 200)
Variable n (%) or mean ± SD
CPB time (min) 182.9  48.4
ACC time (min) 110.9  34.1
Operative time (min) 310.9  73.6
Mitral repair procedure
Ring annuloplasty 199 (99.5)
Quadrangular/triangular resection 89 (44.5)
Neochords formation 91 (45.5)
Commissuroplasty 70 (35.0)
Sliding annuloplasty 6 (3.0)
Cleft repair 5 (2.5)
Chordal transfer 5 (2.5)
Chordal release 3 (1.5)
Leaflet augmentation 2 (1.0)
Papillary muscle repositioning 1 (0.5)
Concomitant procedures
Maze procedure 44 (22.0)
TAP 26 (13.0)
ASD/PFO closure 25 (12.5)
LA reduction 19 (9.5)
LA appendage resection 3 (1.5)
ACC, Aortic crossclamping; ASD, atrial septal defect;CPB, cardiopulmonary bypass;
LA, left atrium; PFO, patent foramen ovale; SD, standard deviation; TAP, tricuspid
annuloplasty.
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predischarge, the successful repair rate was 98.0% because
moderate MR was diagnosed in 4 patients (Figure 1). The
mean CPB and ACC times were 182.9  48.4 minutes
and 110.9 34.1 minutes, respectively. The mean operative
time was 310.9  73.6 minutes.
Complex anterior repair techniques were performed on
95 patients (47.5%). The variety of repair techniques is
shown in Table 2. Annuloplasty rings were used in 99.5%
of patients; the ring was not used in only 1 patient whose
annulus size was small (<26 mm).
Clinical Outcomes
Postoperative outcomes are reported in Table 3. There
was no in-hospital mortality, and the median hospital stay
was 6 days. Postoperative complications developed in 17
patients, including reoperation for bleeding in 10 patients
(5.0%), stroke in 2 patients (1.0%), new-onset renal failureThe Journal of Thoracic and Carin 1 patient (0.5%), low cardiac output syndrome in 1
patient (0.5%), and wound problems in 2 patients (1.0%).
Reoperation was necessary in 2 patients (1.0%): One
reoperation was required because of eccentric MR with
hemolysis caused by a loosened artificial chorda on
postoperative day 26, and the other was due to aortic
dissection originated from the root cannulation site and
required ascending and hemi-arch aortic replacement on
postoperative day 3. Both patients survived to discharge.diovascular Surgery c Volume 148, Number 6 2775
TABLE 3. Postoperative outcomes and complications (n ¼ 200)
Variable n (%) or mean ± SD
Early death (<30 d) 0 (0)
Hospital stay, d (IQR) 6 (5-8)
ICU stay, h (IQR) 23 (20-40)
Mechanical ventilation (>24 h) 10 (5.0)
Complications
Reoperation for bleeding 10 (5.0)
ARF requiring dialysis 1 (0.5)
Low cardiac output 1 (0.5)
Stroke 2 (1.0)
Thromboembolic event 1 (0.5)
Thoracotomy wound 1 (0.5)
Groin wound 1 (0.5)
Permanent pacemaker insertion 0 (0)
Pneumonia 0 (0)
Reoperation 2 (1.0)
For MR* 1 (0.5)
Other (eg, aortic dissection)y 1 (0.5)
Late mortality 4 (2.0)
Last echocardiographic data (>6 mo) (n ¼ 187)
LV ejection fraction (%) 59.7  5.6
LV systolic dimension (mm) 32.1  5.1
LV diastolic dimension (mm) 49.1  5.2
LA dimension (mm) 39.6  6.9
RV-RA DP (mm Hg) 21.7  6.5
ARF, Acute renal failure; IQR, interquartile range; ICU, intensive care unit; LA, left
atrial; LV, left ventricular;MR, mitral regurgitation; RV-RADP, right ventricular-right
atrial pressure gradient; SD, standard deviation. *One patient underwent reoperation
for MR due to a loosened artificial chorda. yAscending aorta and hemi-arch replace-
ment was performed for aortic dissection that was detected on postoperative day 3.
FIGURE 2. Kaplan–Meier curve for freedom from major adverse
cardiac and cerebrovascular events. MACCE, Major adverse cardiac and
cerebrovascular events.
FIGURE 3. Kaplan–Meier curve for freedom from moderate or greater
MR. MR, Mitral regurgitation.
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patients (96.5%). Late death occurred in 4 patients. At a
median of 31.4 months (IQR, 12.4-42.3 months), freedom
from major adverse cardiac and cerebrovascular events at
5 years was 87.7%  5.1% (Figure 2).
Echocardiographic Outcomes
Serial echocardiographic data extending 6 months or
more from the time of surgery were available for 187
patients (93.5%). Among 4 patients with moderate MR at
predischarge, 1 underwent reoperation, 1 spontaneously
developed mild MR, 1 developed severe MR, and 1
maintained moderate MR (Figure 1). Over a median
follow-up period of 29.6 months (IQR, 14.9-45.8 months),
21 patients (10.5%) developed moderate or greater MR
(Figure 1). Freedom frommoderate or greater MR at 5 years
was 87.0%  2.6% (Figure 3).
Change in Procedural Time by the Number of Cases
Both CPB and ACC times decreased as experience
increased, demonstrating statistical significance according
to the chronologic date of the procedure (r ¼ 0.225,
P ¼ .001 and r ¼ 0.378, P < .001, respectively)
(Figure 4, A and B). Main procedural time also improved.2776 The Journal of Thoracic and Cardiovascular SurHowever, total operative time (skin-to-skin), which
includes preparation time required for robot docking and
bleeding control, did not improve (r ¼ 0.121, P ¼ .089)
(Figure 4, C).DISCUSSION
The advantages of MICS, such as decreased postopera-
tive pain and length of hospital stay, and improved
cosmesis, patient satisfaction, and postoperative recovery,
are well known.11,12 The da Vinci surgical system
facilitates MICS by using 3-dimensional high-definition
imaging, sophisticated micro-instrumentation with wrist-
like articulation, and tremor filtration, thereby allowing
MV repair with the least degree of surgical trauma.4,5,7,13
Despite these obvious benefits and favorable results, itsgery c December 2014
FIGURE4. Pearson’s correlation curves for changes in (A) cardiopulmonary bypass time (CPB), (B) aortic cross-clamp time (ACC), and (C) total operative
times based on the chronologic date of mitral repairs.
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because of concerns about safety, complexity, prolonged
surgical time, and the high cost of the procedure.14,15
However, these concerns are primarily related to the
uncertainty of performing various repair techniques using
a telemanipulative device that lacks tactile feedback and
whether MV repair can be successfully and completely
performed.
Safety and Efficacy of Mitral Valve Repair
Safety issues regarding robotic MICS were frequently
raised by critics during the early days of development.
The general concerns were that a reduced surgical field
and using instrumentation without tactile feedback would
increase the complexity of the procedure and surgical risks.
The increased incidence of stroke was particularly
important and related to the use of retrograde perfusion
via femoral arterial cannulation during MICS.16,17
Nonetheless, the rapid development and refinement of
techniques enabled complex MICS valve surgery to be
performed with results equivalent to those of conventional
valve surgery at experienced centers.2 According to a recent
systematic review of studies on robotic MV surgery,6 the
majority of studies report early mortality rates less than
1.0%. In agreement with these reports, this study reports
no in-hospital mortality and low rates of major complica-
tions, including a stroke incidence of 1.0% (Table 3).The Journal of Thoracic and CarAs claimed by Suri and colleagues,18 preoperative
computed tomography screening and avoidance of femoral
arterial cannulation in the presence of atherosclerotic
burden are solutions to the stroke problem.
To validate robotic MV repair, both safety issues and
surgical completeness need to be addressed. According to
a recent review,6 the rate of early postoperative failure
that required reoperation ranges from 1.5% to 5.4%, and
immediate postoperative echocardiography demonstrates
that 81.7% to 97.6% of patients have no or only trace
MR.We report a successful MV repair rate of 98.0% during
the immediate postoperative period without intraoperative
conversion to sternotomy. Mitral reoperation was required
in only 1 patient (Table 3).
In regard to the durability of the repaired MV using the
MICS approach, most previous studies focused only on
survival and mitral reoperation rates.19 To the best of our
knowledge, the present study is the first to assess the
midterm echocardiographic durability of MV on the basis
of the results of regular follow-up examinations. Freedom
from significant MR at 5 years was 87.0%  2.6%
(Figure 3). This seems to be good in comparison with
recent data published by our institution,20 where serial
echocardiographic follow-up was completed in more than
90% of patients who underwent MV through minithora-
cotomy or sternotomy and 5-year freedom from MR
recurrence rates were 86.1% and 85.3%, respectively.diovascular Surgery c Volume 148, Number 6 2777
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Procedures
In MV repair, anterior or bileaflet prolapse is considered
more difficult to repair than posterior leaflet prolapse,
requiring more advanced techniques and greater
expertise, and is associated with an increased risk of mitral
reoperation.21-23 The repair of anterior prolapse using
robotic MV repair is also controversial. The general
opinion is that complex repair techniques, such as
neochords formation, are difficult to perform using robotic
instruments because of the lack of tactile feedback.3
Although the proportion of anterior leaflet involvement
was relatively high (47.5%) (Table 1), various repair
techniques could be used. Furthermore, anterior leaflet
involvement did not increase the risk of MR recurrence
according to the univariate Cox regression analysis
(relative risk, 1.07; 95% confidence interval, 0.47-2.48;
P ¼ .87).
In support of our results, the largest study on robotic MV
repair for anterior or bileaflet prolapse by Rodriguez and
colleagues3 reported that these procedures can be safely
performed without device-related complications. Suri and
colleagues18 also concluded that robotic MV repair allows
the complete anatomic correction of all types of leaflet
prolapse using repair techniques that are identical to those
used in open approaches.
Another important finding of the present study is that the
rates of other concomitant cardiac procedures were high
(Table 2). Concomitant AF ablation was performed on 44
patients (22.0%), which is higher than in the study by
Nifong and colleagues,24 in which the concomitant
CryoMaze procedure was performed on 15.9% of patients.
Among 45 patients with preoperative AF, ablation
procedures were performed in 44 (97.8%). These results
illustrate that various repair techniques and concomitant
procedures can be performed using the da Vinci system.
Learning Period Effect
There was a definite improvement in the main procedural
time as experience increased (Figure 4). However, total
operative time (skin-to-skin), which included time for prep-
aration and bleeding control, demonstrated no significant
improvement. In 2002, we started using the AESOP 3000
system (Computer Motion, Santa Barbara, Calif) and
reported favorable results.20 Because the same repair
techniques were performed using the da Vinci approach,
the learning curve for the console surgeon was virtually
nonexistent. However, 5 separate bedside surgeons were
involved in the early period of our robotic MICS program,
rather than only a dedicated bedside surgeon. It is well
known that the participation of a skilled bedside surgeon
is useful and critical to robotic operations,18 and a study
reported that the presence of a dedicated bedside surgeon
improves operative times during robotic MV surgery.252778 The Journal of Thoracic and Cardiovascular SurThe high rate of reoperation for bleeding complications
(5.0%) (Table 3), which is the most critical weakness of
our data, could be due to the absence of a dedicated bedside
surgeon. All reoperations for bleeding were performed
through the previous working incision without thoracotomy
extension, and the bleeding foci mainly included the port
sites and intercostal muscles.
Surgical volume and learning curve effects are important
for maintaining surgical quality. In this regard, our robotic
MICS program demonstrates a significant weakness
because of the 5 different bedside surgeons and different
team members (ie, anesthesiologists and scrub nurses).
In an effort to improve the quality of our robotic MICS
program, we adopted several new institutional strategies
in 2012. Robotic MICS is now performed by 1 dedicated
bedside surgeon, and we now use the Glauber clamp
(Sorin Group, Saluggia, Italy)26 to reduce bleeding control
time and the risk of port-site bleeding, because this clamp
obviates the need for an extra port incision and facilitates
easier bleeding control. After these changes, 50 consecutive
robotic MV repairs were performed, and there were no
instances of bleeding complications.
The learning curves for cardiac surgery tend to develop
when new assistive technologies are introduced. The
learning curve is especially steep for robotic MV repairs:
thus, using a team of highly experienced members with a
strong history of good outcomes after MV repair via
sternotomy or minithoracotomy is of the utmost importance
before initiating a robotic repair program.18Study Limitations
This study is subject to the inherent limitations of
retrospective observational studies, and the study
population was relatively small. As previously mentioned,
the number of patients is small mainly because robotic
MV repair is still limited to only a few centers in Korea.CONCLUSIONS
RoboticMV repair is technically feasible and efficacious,
and the repaired MV demonstrates favorable midterm
echocardiographic durability. Moreover, procedural times
improve as the experience of the clinicians increases. In
addition, it is possible to perform various repair techniques
and concomitant cardiac procedures that are identical to
those used in open approaches. Long-term follow-up
studies are needed to confirm these observations.References
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